Furthermore, exon 16 skipping HER2 deletion (HER2D16) leads to osimertinib resistance, and unlike in breast cancer, HER2D16 mediates resistance in NSCLC through a Src-independent mechanism, making it insensitive to Src inhibitors (45). This evidence concerns the gene SRC and breast carcinoma.